New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2012
06:55 EDTCRTX, CRTX, CRTX, ACOR, ACOR, ACOR, JNJ, JNJ, JNJ, DNA, DNA, DNA, LLY, LLY, LLY, MYL, MYL, MYL, IPXL, IPXL, IPXL, VRTX, VRTX, VRTX, NVS, NVS, NVS, AMLN, AMLN, AMLNInstitute for International Research to host a summit
4th Annual Government Programs Summit is being held in Baltimore on March 14-16.
News For AMLN;NVS;VRTX;IPXL;MYL;LLY;DNA;JNJ;ACOR;CRTX From The Last 14 Days
Check below for free stories on AMLN;NVS;VRTX;IPXL;MYL;LLY;DNA;JNJ;ACOR;CRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 11, 2014
07:16 EDTIPXLImpax resubmits new drug application to FDA for Rytary
Subscribe for More Information
April 10, 2014
10:47 EDTIPXL High option volume stocks: KOG PIP IPXL ADP EWH
Subscribe for More Information
07:24 EDTDNAInternational Society for Heart & Lung Transplantation to hold annual meeting
Subscribe for More Information
April 9, 2014
08:03 EDTLLYEli Lilly and T1D to partner in diabetes research collaboration
Subscribe for More Information
07:23 EDTJNJEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
07:09 EDTNVSReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Subscribe for More Information
07:09 EDTJNJJohnson & Johnson outlook positive into Q1 results, says Bernstein
Bernstein expects Johnson & Johnson's Q1 EPS to come in slightly above the consensus estimate, with strength in pharmaceuticals more than offsetting lackluster Medical Devices & Diagnostics growth, according to the firm. Bernstein keeps an Outperform rating on the stock.
05:57 EDTMYLMylan implied volatility of 47 at upper end of index mean range
April 8, 2014
11:03 EDTLLYPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
10:03 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTLLYEli Lilly to challenge verdict in Terrence Allen, et al. v. Takeda case
Subscribe for More Information
08:39 EDTLLYTakeda to challenge award of $6B in punitive damages, Lilly ordered to pay $3B
Takeda Pharmaceuticals (TKPYY) announced last night that in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America the jury found in favor of the plaintiffs and awarded $1.475M in compensatory damages. The allocation of liability was 75% Takeda and 25% Eli Lilly (LLY). The jury also awarded $6B in punitive damages from Takeda and $3B from co-defendant, Eli Lilly. “Takeda respectfully disagrees with the verdict and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal. We have empathy for the Allens, but we believe the evidence did not support a finding that ACTOS caused his bladder cancer. We also believe we demonstrated that Takeda acted responsibly with regard to ACTOS,” said Kenneth Greisman, senior vice president, general counsel, Takeda. Reference Link
08:26 EDTLLYEli Lilly upgraded at BMO Capital
Subscribe for More Information
07:56 EDTMYLMylan volatility elevated at 42
Subscribe for More Information
07:26 EDTJNJElsevier Business Intelligence to hold a conference
Subscribe for More Information
07:22 EDTNVSCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.
06:24 EDTLLYEli Lilly upgraded to Market Perform from Underperform at BMO Capital
Subscribe for More Information
April 7, 2014
07:27 EDTNVSAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
05:32 EDTNVSNovartis Bexsero vaccine receives FDA Breakthrough Therapy designation
Novartis announced that Bexsero, Meningococcal Group B Vaccine, has received a Breakthrough Therapy designation from the FDA. Bexsero is already approved in Europe, Canada and Australia to help protect against invasive meningococcal disease caused by serogroup B. Novartis plans to file for U.S. licensure of Bexsero as early as Q2; exact timing will depend on guidance from the FDA. This is the fourth Breakthrough Therapy designation for Novartis, underscoring leadership in developing innovative therapies and vaccines. This announcement comes on the heels of a landmark decision from regulators in the UK, where the Joint Committee on Vaccination and Immunisation recommended the inclusion of Bexsero in the country's National Immunisation Programme for routine use in infants from two months of age.
April 6, 2014
13:57 EDTLLYLilly to present data from bemaciclib as potential treatment for breast cancer
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use